Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Obstructive sleep apnea is a condition that disrupts rest, leading to symptoms such as daytime fatigue, brain fog and ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Decreased blood flow of the optic nerve head (MA, MV, and MT measurements) was significantly correlated with increased OSA ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Short-term HRV is significantly associated with poor daytime psychomotor vigilance performance among both men and women with ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.